ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 55c

ImmunityBio, Inc. (NASDAQ: IBRX) reported Q1 EPS of ($0.62), $0.55 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $44.21 million versus the consensus estimate of $43.07 million.

For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.

You May Also Be Interested In

• Canaccord Starts BillionToOne Inc (BLLN) at Buy
• Broadcom (AVGO) call put ratio 1.6 calls to 1 put into quarter results
• MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance